Low-risk neuroblastoma (INRG very low and low risk, including stage MS): lines of therapy
4 standard-of-care settings across 1 lines and 2 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
Other settings
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Stage MS | Observation; carboplatin and etoposide or low-dose cyclophosphamide for a rapidly enlarging liver or respiratory compromise. | NCI PDQ: Neuroblastoma Treatment (health professional version) | 82 | |
| All comers | Follow-up | Ultrasound and urinary catecholamines, tapering over years; late-effects follow-up for the few who received chemotherapy. | NCI PDQ: Neuroblastoma Treatment (health professional version) | 40 | |
| Age group | L1 tumours and small adrenal masses in infants | Observation with serial ultrasound and urinary catecholamines, or surgical resection; no chemotherapy. | NCI PDQ: Neuroblastoma Treatment (health professional version) | 63 | |
| Age group | L2 tumours in infants with favourable biology | Expectant observation or surgery; short carboplatin and etoposide or cyclophosphamide only for symptoms or threat to organs. | NCI PDQ: Neuroblastoma Treatment (health professional version) | 82 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.